89 related articles for article (PubMed ID: 798190)
1. Higher than usual dosage of haloperidol: a pilot study in chronic schizophrenics.
Pacquay M; Brasseur F
Proc R Soc Med; 1976; 69 suppl 1(Suppl 1):46-9. PubMed ID: 798190
[TBL] [Abstract][Full Text] [Related]
2. Higher than usual dosage of haloperidol: a pilot study in 'back ward' schizophrenics.
Tanghe A; Declercq H
Proc R Soc Med; 1976; 69 suppl 1(Suppl 1):50-3. PubMed ID: 798191
[TBL] [Abstract][Full Text] [Related]
3. A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients.
Tuason VB
J Clin Psychiatry; 1986 Mar; 47(3):126-9. PubMed ID: 3512535
[TBL] [Abstract][Full Text] [Related]
4. Flupenthixol in chronic schizophrenic inpatients: a controlled comparison with haloperidol.
Ehmann TS; Delva NJ; Beninger RJ
J Clin Psychopharmacol; 1987 Jun; 7(3):173-5. PubMed ID: 3298328
[TBL] [Abstract][Full Text] [Related]
5. Psychopharmacological correlates of post-psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia.
Abuzzahab FS; Zimmerman RL
J Clin Psychiatry; 1982 Mar; 43(3):105-10. PubMed ID: 7037757
[TBL] [Abstract][Full Text] [Related]
6. Acutely psychotic patients receiving high-dose haloperidol therapy.
Remington G; Pollock B; Voineskos G; Reed K; Coulter K
J Clin Psychopharmacol; 1993 Feb; 13(1):41-5. PubMed ID: 8486816
[TBL] [Abstract][Full Text] [Related]
7. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U
Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612
[TBL] [Abstract][Full Text] [Related]
8. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
Akhondzadeh S; Safarcherati A; Amini H
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
[TBL] [Abstract][Full Text] [Related]
9. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients.
Ko GN; Korpi ER; Kirch DG
J Clin Psychopharmacol; 1989 Jun; 9(3):186-90. PubMed ID: 2661607
[TBL] [Abstract][Full Text] [Related]
10. Loxapine succinate: a double-blind comparison with haloperidol and placebo in acute schizophrenics.
Selman FB; McClure RF; Helwig H
Curr Ther Res Clin Exp; 1976 Jun; 19(6):645-52. PubMed ID: 819222
[No Abstract] [Full Text] [Related]
11. Somatosensory-evoked potential changes during haloperidol treatment of chronic schizophrenics.
Saletu B; Saletu M; Itil T; Marasa J
Biol Psychiatry; 1971; 3(4):299-307. PubMed ID: 5163816
[No Abstract] [Full Text] [Related]
12. Cis(Z)-clopenthixol and haloperidol in chronic schizophrenic patients--a double-blind clinical multicentre investigation.
Heikkilä L; Laitinen J; Vartiainen H
Acta Psychiatr Scand Suppl; 1981; 294():30-8. PubMed ID: 7041517
[TBL] [Abstract][Full Text] [Related]
13. Comparison of injectable molindone and haloperidol followed by oral dosage forms in acutely ill schizophrenics.
Escobar JI; Mann JJ; Keller J; Wilkins J; Mason B; Mills MJ
J Clin Psychiatry; 1985 Aug; 46(8 Pt 2):15-9. PubMed ID: 3894337
[TBL] [Abstract][Full Text] [Related]
14. Haloperidol in overt ambulatory schizophrenics.
Darling HF
Dis Nerv Syst; 1973; 34(7):364-7. PubMed ID: 4782293
[No Abstract] [Full Text] [Related]
15. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of haloperidol by -methyldopa in the treatment of schizophrenic patients.
Chouinard G; Serrano PM; Tetreault L
Curr Ther Res Clin Exp; 1973 Jul; 15(7):473-83. PubMed ID: 4198310
[No Abstract] [Full Text] [Related]
17. Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol.
Gallhofer B; Jaanson P; Mittoux A; Tanghøj P; Lis S; Krieger S
Pharmacopsychiatry; 2007 Nov; 40(6):275-86. PubMed ID: 18030652
[TBL] [Abstract][Full Text] [Related]
18. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate.
Youssef HA
Clin Neuropharmacol; 1991; 14 Suppl 2():S16-21; discussion S22-3. PubMed ID: 1684308
[TBL] [Abstract][Full Text] [Related]
19. Depressive symptoms and schizophrenia a psychopharmacological approach.
Mauri MC; Bravin S; Fabiano L; Vanni S; Boscati L; Invernizzi G
Encephale; 1995; 21(5):555-8. PubMed ID: 8529564
[TBL] [Abstract][Full Text] [Related]
20. High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin.
Bjørndal N; Bjerre M; Gerlach J; Kristjansen P; Magelund G; Oestrich IH; Waehrens J
Psychopharmacology (Berl); 1980 Jan; 67(1):17-23. PubMed ID: 6768075
[No Abstract] [Full Text] [Related]
[Next] [New Search]
